163 related articles for article (PubMed ID: 28463227)
1. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Norris JD; Ellison SJ; Baker JG; Stagg DB; Wardell SE; Park S; Alley HM; Baldi RM; Yllanes A; Andreano KJ; Stice JP; Lawrence SA; Eisner JR; Price DK; Moore WR; Figg WD; McDonnell DP
J Clin Invest; 2017 Jun; 127(6):2326-2338. PubMed ID: 28463227
[TBL] [Abstract][Full Text] [Related]
2. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
4. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
Attard G; Richards J; de Bono JS
Clin Cancer Res; 2011 Apr; 17(7):1649-57. PubMed ID: 21372223
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
Pollock JA; Wardell SE; Parent AA; Stagg DB; Ellison SJ; Alley HM; Chao CA; Lawrence SA; Stice JP; Spasojevic I; Baker JG; Kim SH; McDonnell DP; Katzenellenbogen JA; Norris JD
Nat Chem Biol; 2016 Oct; 12(10):795-801. PubMed ID: 27501397
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Peer CJ; Schmidt KT; Kindrick JD; Eisner JR; Brown VV; Baskin-Bey E; Madan R; Figg WD
Cancer Chemother Pharmacol; 2019 Oct; 84(4):759-770. PubMed ID: 31367790
[TBL] [Abstract][Full Text] [Related]
7. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
8. Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.
Banuelos CA; Tavakoli I; Tien AH; Caley DP; Mawji NR; Li Z; Wang J; Yang YC; Imamura Y; Yan L; Wen JG; Andersen RJ; Sadar MD
J Biol Chem; 2016 Oct; 291(42):22231-22243. PubMed ID: 27576691
[TBL] [Abstract][Full Text] [Related]
9. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
[No Abstract] [Full Text] [Related]
10. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells.
Qin Z; Ou S; Xu L; Sorensen K; Zhang Y; Hu DP; Yang Z; Hu WY; Chen F; Prins GS
Chem Biol Drug Des; 2021 May; 97(5):1059-1078. PubMed ID: 33470049
[TBL] [Abstract][Full Text] [Related]
11. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.
Lim M; Otto-Duessel M; He M; Su L; Nguyen D; Chin E; Alliston T; Jones JO
ACS Chem Biol; 2014 Mar; 9(3):692-702. PubMed ID: 24354286
[TBL] [Abstract][Full Text] [Related]
12. CYP17 inhibitors for prostate cancer therapy.
Vasaitis TS; Bruno RD; Njar VC
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
[TBL] [Abstract][Full Text] [Related]
13. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.
Sugawara T; Lejeune P; Köhr S; Neuhaus R; Faus H; Gelato KA; Busemann M; Cleve A; Lücking U; von Nussbaum F; Brands M; Mumberg D; Jung K; Stephan C; Haendler B
Oncotarget; 2016 Feb; 7(5):6015-28. PubMed ID: 26760770
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.
Sena LA; Kumar R; Sanin DE; Thompson EA; Rosen DM; Dalrymple SL; Antony L; Yang Y; Gomes-Alexandre C; Hicks JL; Jones T; Bowers KA; Eskra JN; Meyers J; Gupta A; Skaist A; Yegnasubramanian S; Luo J; Brennen WN; Kachhap SK; Antonarakis ES; De Marzo AM; Isaacs JT; Markowski MC; Denmeade SR
J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36194476
[TBL] [Abstract][Full Text] [Related]
15. Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.
Bedoya DJ; Mitsiades N
Onco Targets Ther; 2013; 6():9-18. PubMed ID: 23319868
[TBL] [Abstract][Full Text] [Related]
16. Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
Fizazi K; Bernard-Tessier A; Roubaud G; Utriainen T; Barthélémy P; Fléchon A; van der Voet J; Gravis G; Ratta R; Jones R; Parikh O; Tanner M; Antonarakis ES; Baldini C; Peters N; Garratt C; Ikonen T; Pohjanjousi P; Joensuu H; Cook N
NEJM Evid; 2024 Jan; 3(1):EVIDoa2300171. PubMed ID: 38320513
[TBL] [Abstract][Full Text] [Related]
17. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
18. Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.
Féau C; Arnold LA; Kosinski A; Zhu F; Connelly M; Guy RK
ACS Chem Biol; 2009 Oct; 4(10):834-43. PubMed ID: 19645433
[TBL] [Abstract][Full Text] [Related]
19. Friedelin, a novel inhibitor of CYP17A1 in prostate cancer from
Joshi BP; Bhandare VV; Vankawala M; Patel P; Patel R; Vyas B; Krishnamurty R
J Biomol Struct Dyn; 2023 Nov; 41(19):9695-9720. PubMed ID: 36373336
[TBL] [Abstract][Full Text] [Related]
20. Darolutamide (ODM-201) for the treatment of prostate cancer.
Shore ND
Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]